Table 4.
AER of all and specific subsequent primary neoplasms after specific first primary neoplasm by time from diagnosis, with percentage of total AER contributed by specific subsequent primary neoplasms
|
5–9 years |
10–19 years |
20–29 years |
≥30 years |
p value† | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Obs/exp | AER per 10 000 person-years (95% CI) | % of total AER* | Obs/exp | AER per 10 000 person-years (95% CI) | % of total AER* | Obs/exp | AER per 10 000 person-years (95% CI) | % of total AER* | Obs/exp | AER per 10 000 person-years (95% CI) | % of total AER* | |||
| First primary neoplasm: female breast | ||||||||||||||
| Total subsequent primary neoplasms‡ | 371/190·4 | 11·7 (9·3 to 14·2) | 100% | 730/391·7 | 19·6 (16·5 to 22·6) | 100% | 581/338·5 | 34·5 (27·8 to 41·2) | 100% | 195/149·0 | 25·6 (10·4 to 40·8) | 100% | <0·0001 | |
| Corpus uteri | 46/9·9 | 2·3 (1·5 to 3·2) | 19·7% | 100/36·0 | 3·7 (2·6 to 4·8) | 18·9% | 51/36·8 | 2·0 (0·0 to 4·0) | 5·8% | 7/12·9 | −3·3 (−6·2 to −0·4) | ..§ | 0·97 | |
| Ovary | 74/20·6 | 3·5 (2·4 to 4·6) | 29·9% | 128/43·0 | 4·9 (3·6 to 6·2) | 25·0% | 71/31·2 | 5·7 (3·3 to 8·0) | 16·4% | 18/10·1 | 4·4 (−0·2 to 9·0) | 15·2% | 0·50 | |
| Other female genital | 38/30·9 | 0·5 (−0·3 to 1·2) | 4·3% | 50/33·1 | 1·0 (0·2 to 1·8) | 5·1% | 18/13·7 | 0·6 (−0·6 to 1·8) | 1·7% | 5/4·3 | 0·4 (−2·1 to 2·8) | 1·4% | 0·25 | |
| Colorectal | 24/19·8 | 0·3 (−0·3 to 0·9) | 2·6% | 63/51·6 | 0·7 (−0·2 to 1·6) | 3·6% | 65/51·9 | 1·9 (−0·4 to 4·1) | 5·5% | 27/26·9 | 0·1 (−5·6 to 5·7) | 0·3% | 0·13 | |
| Lung | 37/14·6 | 1·5 (0·7 to 2·2) | 12·8% | 112/48·5 | 3·7 (2·5 to 4·9) | 18·9% | 154/58·6 | 13·6 (10·1 to 17·0) | 39·2% | 54/30·5 | 13·1 (5·1 to 21·0) | 45·2% | <0·0001 | |
| Melanoma | 30/23·1 | 0·4 (−0·3 to 1·1) | 3·4% | 45/34·0 | 0·6 (−0·1 to 1·4) | 3·1% | 17/18·1 | −0·2 (−1·3 to 1·0) | ..§ | 8/5·8 | 1·2 (−1·9 to 4·3) | 4·1% | 0·57 | |
| Other | 122/71·5 | 3·3 (1·9 to 4·7) | 28·2% | 232/145·5 | 5·0 (3·3 to 6·7) | 25·5% | 205/128·2 | 10·9 (6·9 to 14·9) | 31·4% | 76/58·4 | 9·8 (0·3 to 19·3) | 33·8% | 0·0001 | |
| First primary neoplasm: cervix | ||||||||||||||
| Total subsequent primary neoplasms¶ | 241/179·6 | 5·7 (2·9 to 8·5) | 100% | 618/509·3 | 6·9 (3·8 to 10·0) | 100% | 609/465·2 | 18·3 (12·2 to 24·5) | 100% | 207/152·9 | 32·3 (15·4 to 49·1) | 100% | <0·0001 | |
| Breast | 89/104·4 | −1·4 (−3·1 to 0·3) | ..§ | 251/294·6 | −2·8 (−4·7 to −0·8) | ..§ | 157/227·0 | −8·9 (−12·1 to −5·8) | ..§ | 35/58·8 | −14·2 (−21·1 to −7·3) | ..§ | ..‖ | |
| Bladder | 11/2·1 | 0·8 (0·2 to 1·4) | 11·3% | 40/8·4 | 2·0 (1·2 to 2·8) | 20·6% | 52/12·9 | 5·0 (3·2 to 6·8) | 18·3% | 23/6·1 | 10·1 (4·5 to 15·7) | 21·7% | <0·0001 | |
| Colorectal | 23/10·4 | 1·2 (0·3 to 2·0) | 16·9% | 66/37·9 | 1·8 (0·8 to 2·8) | 18·6% | 110/46·7 | 8·1 (5·4 to 10·7) | 29·7% | 38/20·0 | 10·7 (3·5 to 17·9) | 23·0% | <0·0001 | |
| Lung | 45/7·3 | 3·5 (2·3 to 4·7) | 49·3% | 101/34·5 | 4·2 (3·0 to 5·5) | 43·3% | 137/52·0 | 10·8 (7·9 to 13·8) | 39·6% | 52/23·2 | 17·2 (8·8 to 25·6) | 37·0% | <0·0001 | |
| Other | 73/55·3 | 1·6 (0·1 to 3·2) | 22·5% | 160/133·9 | 1·7 (0·1 to 3·2) | 17·5% | 153/126·6 | 3·4 (0·3 to 6·5) | 12·5% | 59/44·8 | 8·5 (−0·5 to 17·4) | 18·3% | 0·24 | |
| First primary neoplasm: testicular | ||||||||||||||
| Total subsequent primary neoplasms** | 124/81·9 | 3·8 (1·8 to 5·7) | 100% | 378/246·2 | 9·0 (6·4 to 11·6) | 100% | 605/318·3 | 46·6 (38·8 to 54·4) | 100% | 328/161·1 | 127·0 (100·0 to 154·0) | 100% | <0·0001 | |
| Prostate | †† | †† | †† | 26/20·0 | 0·4 (−0·3 to 1·1) | 4·4% | 79/66·3 | 2·1 (−0·8 to 4·9) | 4·5% | 79/45·7 | 25·3 (12·1 to 38·6) | 19·9% | <0·0001 | |
| Bladder | 9/5·0 | 0·4 (−0·2 to 0·9) | 10·5% | 30/17·4 | 0·9 (0·1 to 1·6) | 10·0% | 84/25·0 | 9·6 (6·7 to 12·5) | 20·6% | 44/14·0 | 22·8 (13·0 to 32·7) | 18·0% | <0·0001 | |
| Colorectal | 16/9·4 | 0·6 (−0·1 to 1·3) | 15·8% | 45/33·4 | 0·8 (−0·1 to 1·7) | 8·9% | 97/44·1 | 8·6 (5·5 to 11·7) | 18·5% | 48/22·3 | 19·6 (9·2 to 29·9) | 15·4% | <0·0001 | |
| Lung | 7/7·1 | −0·0 (−0·5 to 0·5) | 0·0% | 42/32·0 | 0·7 (−0·2 to 1·6) | 7·8% | 83/49·9 | 5·4 (2·5 to 8·3) | 11·6% | 39/26·6 | 9·5 (0·1 to 18·8) | 7·5% | <0·0001 | |
| Other | 91/59·1 | 2·8 (1·2 to 4·5) | 73·7% | 235/143·4 | 6·3 (4·2 to 8·3) | 70·0% | 262/133·0 | 21·0 (15·8 to 26·1) | 45·1% | 118/52·6 | 49·7 (33·5 to 65·9) | 39·1% | <0·0001 | |
| First primary neoplasm: female Hodgkin lymphoma | ||||||||||||||
| Total subsequent primary neoplasms‡‡ | 66/38·6 | 8·0 (3·4 to 12·7) | 100% | 316/104·2 | 44·7 (37·4 to 52·1) | 100% | 374/100·8 | 119·5 (102·9 to 136·1) | 100% | 147/44·6 | 168·6 (129·5 to 207·8) | 100% | <0·0001 | |
| Breast | 20/17·0 | 0·9 (−1·7 to 3·5) | 11·3% | 168/52·0 | 24·5 (19·1 to 29·9) | 54·8% | 181/48·8 | 57·8 (46·3 to 69·3) | 48·4% | 62/18·4 | 71·8 (46·4 to 97·2) | 42·6% | <0·0001 | |
| Lung | 7/1·0 | 1·8 (0·2 to 3·3) | 22·5% | 25/4·8 | 4·3 (2·2 to 6·3) | 9·6% | 48/8·0 | 17·5 (11·6 to 23·5) | 14·6% | 21/5·2 | 26·0 (11·2 to 40·8) | 15·4% | <0·0001 | |
| Other | 39/20·6 | 5·4 (1·8 to 9·0) | 67·5% | 123/47·4 | 16·0 (11·4 to 20·6) | 35·8% | 145/44·0 | 44·2 (33·9 to 54·5) | 37·0% | 64/21·0 | 70·8 (44·9 to 96·6) | 42·0% | <0·0001 | |
| First primary neoplasm: male Hodgkin lymphoma | ||||||||||||||
| Total subsequent primary neoplasms§§ | 51/25·1 | 5·9 (2·7 to 9·1) | 100% | 192/72·9 | 19·5 (15·0 to 23·9) | 100% | 289/105·1 | 60·2 (49·3 to 71·1) | 100% | 171/68·8 | 121·9 (91·3 to 152·4) | 100% | <0·0001 | |
| Lung | 6/2·1 | 0·9 (−0·2 to 2·0) | 15·3% | 56/9·8 | 7·5 (5·2 to 9·9) | 38·8% | 82/17·5 | 21·1 (15·3 to 26·9) | 35·0% | 54/11·9 | 50·2 (33·0 to 67·3) | 41·2% | <0·0001 | |
| Other | 45/23·0 | 5·0 (2·0 to 8·0) | 84·7% | 136/63·1 | 11·9 (8·2 to 15·7) | 61·3% | 207/87·7 | 39·1 (29·8 to 48·3) | 65·0% | 117/56·9 | 71·7 (46·4 to 97·0) | 58·8% | <0·0001 | |
| First primary neoplasm: female thyroid | ||||||||||||||
| Total subsequent primary neoplasms¶¶ | 61/47·0 | 5·0 (−0·5 to 10·5) | 100% | 155/107·8 | 13·6 (6·6 to 20·6) | 100% | 133/95·1 | 23·9 (9·7 to 38·1) | 100% | 48/38·9 | 21·9 (−10·9 to 54·7) | 100% | 0·03 | |
| Breast | 27/22·1 | 1·7 (−1·9 to 5·4) | 34·0% | 63/53·2 | 2·8 (−1·7 to 7·3) | 20·8% | 59/41·2 | 11·2 (1·7 to 20·7) | 46·9% | 21/13·7 | 17·6 (−4·1 to 39·3) | 80·4% | 0·06 | |
| Other | 34/24·9 | 3·3 (−0·8 to 7·3) | 66·0% | 92/54·6 | 10·7 (5·3 to 16·1) | 79·2% | 74/53·9 | 12·7 (2·1 to 23·3) | 53·1% | 27/25·2 | 4·3 (−20·2 to 28·9) | 19·6% | 0·12 | |
AER=absolute excess risk. Obs/exp=observed number of subsequent primary neoplasms/expected number of subsequent primary neoplasms.
The total AER (for the purposes of calculating percentages) after each specific first primary neoplasm is the sum of the positive values for the contributing subsequent primary neoplasms.
Multivariable p value.
All subsequent primary neoplasms in female survivors excluding subsequent primary neoplasms of the breast.
Negative numbers for the AER, represented by …
All subsequent primary neoplasms in female survivors excluding subsequent primary neoplasms of female genital sites.
p value not calculated due to negative AERs for all years.
All subsequent primary neoplasms in male survivors excluding subsequent primary neoplasms of other male genital sites (prostate sites allowed).
Results not reliable because of small number of subsequent primary neoplasms (<5 observed subsequent primary neoplasms).
All solid subsequent primary neoplasms in female survivors (excluding non-solid tumours).
All solid subsequent primary neoplasms in male survivors (excluding non-solid tumours).
All subsequent primary neoplasms in female survivors excluding subsequent primary neoplasms of the thyroid.